Two-Year Follow-Up of Acromegalic Patients Treated with Slow Release Lanreotide (30 mg)¹

Abstract

Pharmacotherapy of acromegaly has been improved in recent years as new long-acting somatostatin analogs have became available; they have been suggested as an alternative treatment to pituitary surgery and radiotherapy. To avoid the inconvenience of multiple daily injections during long-term therapy, a slow release formulation of lanreotide (LAN), to be administered im at a dose of 30 mg every 7-14 days, has been introduced in the therapeutic management. The suppressive effects of a short-term LAN treatment on GH and insulin-like growth factor I (IGF-I) hypersecretion were shown to be similar to those obtained with sc octreotide. However, scant data have been reported concerning a long-term treatment with this drug. In the present study the efficacy and tolerability of a 24-month LAN treatment were evaluated in 118 active acromegalic patients; 71 had been previously operated on and treated with sc octreotide (operated patients), 24 previously operated on had been irradiated and treated with sc octreotide (irradiated patients), and the remaining 23 were newly diagnosed (de novo patients). The efficacy was considered on the basis of controlled GH (fasting, Ͻ7.5 mU/L; glucose-suppressed,

MANAGEMENT OF ENDOCRINE DISEASE: Does gender matter in the management of acromegaly?

“…(120). Many other prospective studies have investigated treatment efficacy of lanreotide (seven large recent studies reviewed, total n = 2275), without reporting on gender data (121,122,123,124,125,126,127). Results are similarly limited for octreotide.…”